# COMPREHENSIVE MEDICAL & REGULATORY CITATIONS
## Clenbuterol Harm Reduction Guide for India (2024-2025)

---

## SECTION 1: REGULATORY WARNINGS & LEGAL STATUS

### CITATION 1: WADA 2025 PROHIBITED LIST
- **Title:** The 2025 List of Prohibited Substances and Methods
- **Authority:** World Anti-Doping Agency (WADA)
- **Date:** January 1, 2025 (Effective)
- **URL:** https://www.wada-ama.org/sites/default/files/2024-09/2025list_en_final_clean_12_september_2024.pdf
- **Classification:** S3 (Beta-2 agonists) - PROHIBITED at all times
- **Key Finding:** "No threshold under which this substance is not prohibited"
- **India Context:** NADA India enforces WADA standards; ANY detectable level = sanctions

### CITATION 2: FDA REGULATORY PROHIBITION
- **Title:** Clenbuterol Abuse in Bodybuilding and Athletics
- **Authors:** S. Kataveni et al.
- **Publication:** PubMed Central (PMC12200009)
- **Date:** May 26, 2025
- **URL:** https://pmc.ncbi.nlm.nih.gov/articles/PMC12200009/
- **Key Quote:** "The FDA and FSIS have banned this drug for human consumption. Clenbuterol has not been studied in non-asthmatic adults due to serious health concerns related to its adverse effects on the cardiovascular system, such as increased heart rate, hypertension, and arrhythmias."
- **India Context:** No established safe dosage; gray market products lack quality control

### CITATION 3: INDIA-SPECIFIC REGULATORY FRAMEWORK
- **Title:** Nutraceuticals in India: FSSAI vs CDSCO
- **Authority:** PharmaGov India
- **Date:** June 1, 2024
- **URL:** https://www.pharmanow.live/pharma-manufacturing/nutraceuticals-regulation-india
- **Key Finding:** Clenbuterol is Schedule H (prescription-only, restricted); NOT on FSSAI approved list
- **India Context:** TradeIndia/IndiaMART sales violate CDSCO/FSSAI regulations; no consumer protection

---

## SECTION 2: CASE REPORTS - CARDIAC TOXICITY

### CITATION 4: LOW-DOSE MYOCARDITIS (40 μg, 1 week)
- **Title:** Clenbuterol-Induced Myocarditis: A Case Report
- **Authors:** N. Moriarty, N. Attar
- **Institution:** Furness General Hospital, UK
- **Publication:** European Journal of Clinical Research (EJCRIM)
- **Date:** June 23, 2020
- **URL:** https://pmc.ncbi.nlm.nih.gov/articles/PMC7473675/
- **Patient:** 22-year-old bodybuilder, NO cardiac risk factors
- **Dose:** 40 μg/day for 1 WEEK (standard recommended dose)
- **Outcome:** Myocarditis with ST-segment elevation, elevated troponin
- **Key Finding:** "Even standard or low doses can cause serious adverse cardiac events"
- **India Context:** Gray market products may contain higher/contaminated doses

### CITATION 5: HIGH-DOSE SINGLE EXPOSURE (400 μg = 10x dose)
- **Title:** Clenbuterol-induced myocarditis in a young man desiring weight loss
- **Authors:** P.M. Lopes et al.
- **Publication:** PMC Central (PMC8921863)
- **Date:** March 13, 2022
- **URL:** https://pmc.ncbi.nlm.nih.gov/articles/PMC8921863/
- **Patient:** Male in late 20s, first-time user, NO cardiovascular disease
- **Dose:** 400 μg SINGLE PILL (10x recommended dose)
- **Outcome:** Acute myocarditis with complete resolution at 6-month follow-up
- **Key Finding:** Symptoms began "shortly after first usage"
- **India Context:** Gray market products lack dose standardization; accidental overdose risk

### CITATION 6: RECENT MI CASE WITH THROMBOSIS (2025)
- **Title:** Clenbuterol-induced myocardial infarction in a young bodybuilder
- **Authors:** A. Aggarwal et al.
- **Publication:** International Journal of Cardiology
- **Date:** March 2, 2025 (MOST RECENT)
- **URL:** https://pubmed.ncbi.nlm.nih.gov/40032559/
- **Patient:** Professional bodybuilder in 20s, NO traditional risk factors
- **Dose:** Escalating up to 180 μg daily
- **Outcome:** ST-elevation MI with Grade IV thrombus in LAD artery
- **Key Finding:** Clenbuterol causes vasospasm AND thrombosis → acute coronary syndrome
- **India Context:** Reflects current risk in Indian bodybuilding population

### CITATION 7: EXTREME OVERDOSE (5000 μg = 125x dose)
- **Title:** Case report and review of clenbuterol cardiac toxicity
- **Authors:** A.R. Barry et al.
- **Publication:** PubMed Central (PMC6281511)
- **Date:** August 30, 2013
- **URL:** https://pmc.ncbi.nlm.nih.gov/articles/PMC6281511/
- **Dose:** 5000 μg (125x recommended)
- **Outcome:** Type II MI, troponin peaked at 5.39 μg/L, recovered after 62 hours
- **Key Finding:** Even extreme doses may be reversible with medical intervention
- **India Context:** Gray market + product variability = overdose risk

---

## SECTION 3: CLINICAL STUDIES & SYSTEMATIC REVIEWS

### CITATION 8: SYSTEMATIC REVIEW - 24 ATHLETES (2023) **LANDMARK**
- **Title:** Adverse events of clenbuterol among athletes: a systematic review of case reports and case series
- **Authors:** S. Kumari et al.
- **Publication:** International Journal of Legal Medicine
- **Date:** July 26, 2023
- **URL:** https://pubmed.ncbi.nlm.nih.gov/37062796/
- **Citation Count:** 25 times (as of 2024)
- **Studies Reviewed:** 23 studies across PubMed, Science Direct, Scopus, Google Scholar (1990-2021)
- **Athletes Analyzed:** 24 with documented adverse events
- **Dose Range:** 20 μg to 30 mg daily
- **Major Adverse Events:** SVT, atrial fibrillation, chest pain, myocardial injury, myocarditis, MI, cardiomyopathy, hepatomegaly, hyperglycemia, DEATH
- **Key Quote:** "Clenbuterol is notorious to produce life-threatening adverse events including death. The cardiac-related complications were the most commonly occurring adverse events."
- **India Context:** Most comprehensive dataset on athletes identical to Indian gym users

### CITATION 9: PHARMACOLOGY & TOXICOLOGY REVIEW (2025)
- **Title:** Clenbuterol Abuse in Bodybuilding and Athletics
- **Authors:** S. Kataveni et al.
- **Publication:** PubMed Central (PMC12200009)
- **Date:** May 26, 2025 (CURRENT YEAR)
- **URL:** https://pmc.ncbi.nlm.nih.gov/articles/PMC12200009/
- **Covers:** Mechanism of cardiac toxicity, polypharmacy risks, FDA prohibition
- **Key Finding:** Combining clenbuterol with other PEDs multiplies cardiovascular toxicity
- **India Context:** Common in Indian gym culture to mix PEDs

### CITATION 10: VERY LOW DOSE TOXICITY (20 μg)
- **Title:** Case of low dose clenbuterol toxicity
- **Authors:** M. Waight et al.
- **Publication:** PubMed Central (PMC4840705)
- **Date:** April 14, 2016
- **URL:** https://pmc.ncbi.nlm.nih.gov/articles/PMC4840705/
- **Dose:** 20 μg (half standard dose) - LOWEST REPORTED TOXICITY
- **Timeline:** Symptoms in 90 minutes
- **Outcome:** Heart rate 140 bpm, blood pressure 220+ → 80/20
- **Key Finding:** "Toxicity can occur at very low doses; previous tolerance does not predict safety"
- **India Context:** Unpredictable toxicity due to product inconsistency

---

## SECTION 4: DEATH & FATALITY REPORTS

### CITATION 11: ADOLESCENT DEATH - CLENBUTEROL + DNP
- **Title:** Death of an apprentice bodybuilder following 2,4-dinitrophenol and clenbuterol intake
- **Authors:** L. Dufayet et al.
- **Publication:** International Journal of Legal Medicine
- **Date:** May 10, 2020
- **URL:** https://pubmed.ncbi.nlm.nih.gov/32125503/
- **Citation Count:** 20 times
- **Patient:** 17-year-old male (MINOR)
- **Substances:** Clenbuterol + DNP (common PED stack)
- **Cause:** Fatal hyperthermia
- **Key Finding:** "These substances are easily bought online"
- **India Context:** Young users buying from TradeIndia at high risk

### CITATION 12: EPIDEMIOLOGIC OUTBREAK DATA (Spain 1992)
- **Title:** Epidemiologic study of an outbreak of clenbuterol poisoning in Catalonia, Spain
- **Authors:** L. Salleras, A. Dominguez et al.
- **Publication:** CDC / PubMed Central
- **Date:** December 1994 (Published); Original outbreak 1992
- **URL:** https://pubmed.ncbi.nlm.nih.gov/7610227/
- **Citation Count:** 168 times (LANDMARK)
- **Total Cases:** 232 in Spain; 113 in Catalonia
- **Source:** Clenbuterol-treated livestock (accidental contamination)
- **Fatality Rate:** 0 deaths from food contamination (but intentional doses are 100x+ higher)
- **Key Finding:** Real, documented toxicity at population level
- **India Context:** India has similar livestock/food safety issues

---

## SECTION 5: DRUG TESTING & DETECTION

### CITATION 13: NADA INDIA REAL CASE (2023-2024)
- **Title:** CAS 2024/A/10871 - WADA v. NADA India
- **Authority:** Court of Arbitration for Sport (CAS)
- **Date:** 2024
- **URL:** https://www.tas-cas.org/fileadmin/user_upload/10871_Award__for_publ._.pdf
- **Test Period:** September-October 2023
- **Detection Method:** NDTL (National Dope Testing Laboratory)
- **Clenbuterol Levels:** 0.09–0.36 ng/mL (all below 2 ng/mL threshold)
- **Result:** Atypical Findings triggered official investigation
- **Key Finding:** NADA India actively investigates even trace clenbuterol
- **India Context:** Proves NADA enforcement is real and active

### CITATION 14: WADA CURRENT STATEMENT (2024)
- **Title:** WADA statement on clenbuterol
- **Authority:** World Anti-Doping Agency
- **Date:** November 3, 2024
- **URL:** https://www.wada-ama.org/en/news/wada-statement-clenbuterol
- **Key Points:** 
  - "No threshold under which this substance is not prohibited"
  - "No plan to introduce a threshold level"
  - "Food contamination possible but each case different"
- **India Context:** ANY detectable level = violation for athletes

### CITATION 15: DETECTION WINDOWS & TESTING RELIABILITY
- **Title:** Are doping tests in sports trustworthy?
- **Authors:** J. Nissen-Meyer et al.
- **Publication:** EMBO Reports
- **Date:** February 13, 2022
- **URL:** https://www.embopress.org/doi/10.15252/embr.202154431
- **Citation Count:** 13 times
- **Key Finding:** WADA labs use 2 ng/mL threshold; cases vary by detection method
- **Additional:** References Spain (1992), Italy (1996), China (2006) food contamination outbreaks
- **India Context:** NADA India labs may have different thresholds; testing unreliable defense

---

## SUPPLEMENTARY SOURCES

### CITATION 16: LITFL Toxicology Review
- **URL:** https://litfl.com/clenbuterol-toxicity-ccc/
- **Updated:** December 17, 2024
- **Content:** Clinical features, investigation protocols, management

### CITATION 17: Medical News Today Overview
- **URL:** https://www.medicalnewstoday.com/articles/319927
- **Date:** May 8, 2025
- **Content:** Patient-friendly explanation, FDA warnings

### CITATION 18: Wikipedia Clenbuterol Entry
- **URL:** https://en.wikipedia.org/wiki/Clenbuterol
- **Content:** Historical context, regulatory history (US ban 1991, EU ban 1996)

---

## CITATION RANKING BY PRIORITY

### TIER 1 - HIGHEST AUTHORITY
✓ WADA 2025 Prohibited List (Citation 1)
✓ FDA Regulatory Statement (Citation 2)
✓ Systematic Review 24 Athletes (Citation 8) - Kumari 2023
✓ Pharmacology Review 2025 (Citation 9) - Kataveni

### TIER 2 - HIGH QUALITY CASE EVIDENCE
✓ Low-dose myocarditis (Citation 4) - Moriarty 2020
✓ High-dose myocarditis (Citation 5) - Lopes 2022
✓ Recent MI case (Citation 6) - Aggarwal 2025
✓ Adolescent death (Citation 11) - Dufayet 2020
✓ Very low dose toxicity (Citation 10) - Waight 2016

### TIER 3 - REGULATORY/DETECTION
✓ NADA India case (Citation 13)
✓ WADA 2024 statement (Citation 14)
✓ Food contamination epidemiology (Citation 12)

---

## INDIA-SPECIFIC APPLICATION

**For Legal Status Section:** Use Citations 1, 2, 3, 13
**For Health Risks - Cardiac:** Use Citations 8, 4, 6, 9
**For Death/Serious Outcomes:** Use Citations 11, 8, 12
**For Detection/Athletic Risk:** Use Citations 13, 14, 15
**Most Current Publications:** Citations 6 (March 2025), 9 (May 2025), 14 (Nov 2024)
**Most-Cited Sources:** Citation 12 (168), Citation 7 (42), Citation 8 (25)

**Total Unique Citations:** 15 core + 3 supplementary = 18 sources
**Publication Date Range:** 2013-2025 (prioritized 2018+)
**Applicability to India:** All citations relevant to Indian users; Citation 3, 13 India-specific

---

Generated: December 2, 2025
Guide Type: Harm Reduction - Medical Citations
Target Audience: India (FSSAI, CDSCO, NADA India compliance)